Engineering IGF2 for Lysosome‐targeting chimeras development to target drug‐resistant membrane proteins in tumor therapy
Protein Science · 2025-03 · 34 (3)
DOI: 10.1002/pro.70051 ↗Kurz gefasst
Fachartikel in der Zeitschrift Protein Science, online erschienen am 19.02.2025. Verfasst von Yanchao Pan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Translational Research Center, Shenzhen Bay Laboratory, Shenzhen, China. Hauptthemen laut MEDLINE: Lysosomes, Insulin-Like Growth Factor II, Drug Resistance, Neoplasm, Protein Engineering. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Shenzhen Bay Laboratory.
Abstract (Originalsprache)
Lysosome‐targeting chimeras (LYTACs) represent a promising approach for the targeted degradation of membrane proteins. Currently, two primary methods for LYTAC development involve chemically modified antibodies and wild‐type insulin‐like growth factor 2 (IGF2) fusion proteins (iLYTACs). However, LYTACs necessitate intricate chemical modification processes, while wild‐type IGF2 in iLYTAC technology binds to IGF1R, potentially triggering carcinogenesis. To tackle this challenge, we introduce specific IGF2R‐binding lysosomal targeting chimeras (sLYTACs), a novel technology utilizing engineered IGF2 mutant fusion antibodies for the degradation of endogenous membrane proteins. Diverging from iLYTACs, sLYTACs exhibit selective binding to IGF2R with increased affinity, significantly bolstering the anti‐proliferative impact on drug‐resistant tumor cells both in vitro and in vivo. By effectively degrading third‐generation tyrosine kinase inhibitor‐resistant EGFR mutants, masking binding epitope HER2, and concurrently targeting compensatory receptors interacting with these proteins, sLYTACs show great promise in drug development to overcome bypass signaling and combat drug resistance in tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Research Center, Shenzhen Bay Laboratory, Shenzhen, China.
ORCID-Profile: Yanchao Pan
Förderung
- Shenzhen Bay Laboratory
Zitieren
APA
Pan, Y., Xiang, Q., Deng, K., Anwar, M. I., Wang, L., Wang, Y., Liang, Q., Shen, L., Yang, J., Hou, Z., & Shen, W. (2025). Engineering IGF2 for Lysosome‐targeting chimeras development to target drug‐resistant membrane proteins in tumor therapy. Protein Science, 34(3). https://doi.org/10.1002/pro.70051
Vancouver
Pan Y, Xiang Q, Deng K, Anwar MI, Wang L, Wang Y, et al. Engineering IGF2 for Lysosome‐targeting chimeras development to target drug‐resistant membrane proteins in tumor therapy. Protein Science. 2025;34(3). doi:10.1002/pro.70051
BibTeX
@article{Pan2025,
author = {Pan, Yanchao and Xiang, Qing and Deng, Kai and Anwar, Muhammad I and Wang, Leiming and Wang, Yuan and Liang, Qiulian and Shen, Lirou and Yang, Jing and Hou, Zhongyu and Shen, Weijun},
title = {Engineering IGF2 for Lysosome‐targeting chimeras development to target drug‐resistant membrane proteins in tumor therapy},
journal = {Protein Science},
year = {2025},
volume = {34},
number = {3},
doi = {10.1002/pro.70051}
}
EUVIMED